Next report date
Report period
Q4 2023
EPS estimate
−0.62USD
Revenue estimate
—
−5.77 MUSD
4.25 M
About Scinai Immunotherapeutics Ltd.
Sector
CEO
Amir Reichman
Headquarters
Jerusalem
Website
Employees (FY)
33
Founded
2003
FIGI
BBG007TGL1R2
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
